The undertreatment of LDL-cholesterol: addressing the challenge (Q73902389)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10856770%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

title

The undertreatment of LDL-cholesterol: addressing the challenge (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10856770%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

author name string

T A Pearson

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10856770%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

language of work or name

English

0 references

publication date

1 June 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10856770%20AND%20SRC:MED&resulttype=core&format=json

International Journal of Cardiology

7 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10856770%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

volume

74 Suppl 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10856770%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

page(s)

S23-8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10856770%20AND%20SRC:MED&resulttype=core&format=json

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

7 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2899%2900108-4

7 January 2021

Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2899%2900108-4

7 January 2021

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2899%2900108-4

7 January 2021

Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2899%2900108-4

7 January 2021

West of Scotland Coronary Prevention Study: implications for clinical practice. The WOSCOPS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2899%2900108-4

7 January 2021

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2899%2900108-4

7 January 2021

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2899%2900108-4

7 January 2021

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2899%2900108-4

7 January 2021

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2899%2900108-4

7 January 2021

Adherence to National Cholesterol Education Program Treatment goals in postmenopausal women with heart disease. The Heart and Estrogen/Progestin Replacement Study (HERS). The HERS Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2899%2900108-4

7 January 2021

Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2899%2900108-4

7 January 2021

Inadequate treatment with HMG-CoA reductase inhibitors by health care providers

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2899%2900108-4

7 January 2021

The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2899%2900108-4

7 January 2021

10.1016/S0167-5273(99)00108-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10856770%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1 reference